Showing results (291-300 of 537) with videos related to
Sort By:
Pageof 54
Frontiers in Neurology|February 21, 2015
Efficacy and Tolerability of STOPAIN for a Migraine AttackAndrea St Cyr, Ashley Chen, Kathleen C Bradley, et al.Surgical and Radiologic Anatomy : SRA|December 24, 2017
Depicting the pterygopalatine ganglion on 3 Tesla magnetic resonance imagesDaniel Fossum Bratbak, Mari Folvik, Ståle Nordgård, et al.Advances in Therapy|December 7, 2021
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 TrialsAndrew M Blumenfeld, Kerry Knievel, Aubrey Manack Adams, et al.JAMA|November 20, 2019
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical TrialRichard B Lipton, David W Dodick, Jessica Ailani, et al.The New England Journal of Medicine|December 5, 2019
Ubrogepant for the Treatment of MigraineDavid W Dodick, Richard B Lipton, Jessica Ailani, et al.Cephalalgia : an International Journal of Headache|September 24, 2019
Proposed new diagnostic criteria for chronic migraineMona Ameri Chalmer, Thomas Folkmann Hansen, Elena R Lebedeva, et al.Cephalalgia : an International Journal of Headache|May 4, 2018
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trialsRashmi B Halker Singh, Ernesto Aycardi, Marcelo E Bigal, et al.Headache|April 21, 2007
Topiramate in migraine prophylaxis: long-term impact on resource utilization and costStephen D Silberstein, Anthony L Feliu, Marcia F T Rupnow, et al.CNS Drugs|October 13, 2018
From LBR-101 to Fremanezumab for MigraineMarcelo E Bigal, Alan M Rapoport, Stephen D Silberstein, et al.Pageof 54